Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.
US regulators have agreed to review AbbVie and Janssen’s Imbruvica for previously treated chronic graft-versus-host-disease (cGVHD), a severe, potentially life-threatening consequence of stem cell or bone marrow transplant.